Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To decide the problem of adequacy of preoperative treatment and postoperative special therapy, it is necessary to determine the degree of therapeutic pathomorphosis of primary osteogenic sarcoma. According to the materials of the children's clinic of the All-Union Cancer Research Center, USSR AMS, the degree of impairment is dependent on the size of the neoplasm, nature of the treatment and the x-ray-morphological variant. In a group of patients given preoperative chemoradiation treatment for degrees III and IV of therapeutic pathomorphosis, the 5-year survival amounted to 37.9 and 67.2% of cases, respectively. In a weak degree of tumor lesion (I-II), only 7% of the patients survive the 5-year period without metastases. The degree of therapeutic pathomorphosis is of great importance for correcting postoperative therapy as well as for predicting the course of osteogenic sarcoma in children.
 ...
PMID:[Significance of therapeutic pathomorphosis in the treatment and prognosis of osteogenic sarcoma in children]. 176 32

The experience in the management of 246 patients with local osteogenic sarcoma and 67 patients with pulmonary metastases in the All-Union Oncologic Research Center, AMS USSR, is presented here. All the patients underwent surgery, but starting in 1974, various modalities of adjuvant chemotherapy (not randomized) were applied in addition. In the surgery alone group, prognosis was very poor: only 7.0% of patients survived free of disease 5 years from the primary tumor treatment. Adjuvant chemotherapy (adriamycin + vincristine + melphalan + cyclophosphamide) following amputations increased this rate to 34.0%; combining segmental resections of an affected bone with preoperative intraarterial adriamycin infusion and radiation (36 Gy) increased the rate to 35.5%. In patients with grade 4 tumor damage (tumor cells are not found upon examination of a large number of sections), the rate increased to 57.9% (P less than .05). Another regimen of adjuvant chemotherapy (platidiam or cisplatin + adriamycin + cyclophosphamide) gives a chance to 78.8% of patients to survive 1 year free of metastases. The same chemotherapy regimen enables us to achieve an objective effect in 30.8% of patients with pulmonary metastases, and its combination with surgical metastasis ablation makes it possible to obtain a complete remission, lasting from 2 to 46 months (average 13.9 months). Toxic manifestations of the chemotherapy regimens considered are moderate. Prognosis in adjuvant chemotherapy is related to age, tumor site, its local dissemination, and morphologic type of osteogenic sarcoma.
 ...
PMID:Management of osteogenic sarcoma patients. 346